Peptide Database

CJC-1295 with DAC · DAC:GRF

CJC-1295 is a modified GHRH analog with a Drug Affinity Complex (DAC) that binds to serum albumin, dramatically extending its half-life compared to native GHRH. It produces sustained elevation of GH and IGF-1 levels over days rather than hours. Research focuses on body composition improvements, muscle growth, and fat loss through prolonged GH axis stimulation.

C₁₅₂H₂₅₂N₄₂O₄₂S · 3647.28 Da

Growth Hormone-Releasing Hormone · Somatoliberin

GHRH is the endogenous 44-amino-acid hypothalamic peptide that drives the pulsatile secretion of growth hormone from the anterior pituitary. Native GHRH acts through GHRHR, stimulating GH gene transcription and secretion. It has a very short half-life in vivo, making it impractical as a therapeutic — which drove the development of modified analogs like sermorelin, CJC-1295, and tesamorelin. Research into GHRH receptor signaling underpins the entire GH secretagogue drug class.

Sandostatin · SMS 201-995

Octreotide is a synthetic 8-amino-acid somatostatin analog with a much longer half-life than native somatostatin. FDA-approved for acromegaly, carcinoid syndrome, VIPomas, and variceal bleeding, it is also used off-label for Cushing's disease, thyroid cancer, and refractory diarrhea. Long-acting release (LAR) formulations allow monthly dosing. It is among the most clinically important peptide drugs in endocrinology.

GHRH(1-29) · GRF 1-29 NH2

Sermorelin is a synthetic analog of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It stimulates the pituitary to produce and secrete growth hormone in a pulsatile, physiologic manner. FDA-approved for GH deficiency in children, it is extensively researched in adults for body composition, sleep quality, and age-related GH decline.

C₁₄₉H₂₄₆N₄₄O₄₂S · 3357.88 Da

SRIF · Somatotropin Release-Inhibiting Factor

Somatostatin is a 14-amino-acid cyclic peptide and the primary endogenous inhibitor of growth hormone secretion. It also inhibits insulin, glucagon, gastrin, cholecystokinin, and secretin release, slows GI motility, and reduces splanchnic blood flow. Its short half-life drove the development of longer-acting analogs (octreotide, lanreotide) used clinically for acromegaly, neuroendocrine tumors, and GI bleeding.

Egrifta · TH9507

Tesamorelin is a stabilized synthetic GHRH analog FDA-approved for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. It stimulates pulsatile GH secretion while preserving natural feedback regulation. Research demonstrates significant visceral adipose tissue reduction, improved lipid profiles, and cognitive benefits, making it a key study compound for metabolic dysfunction.